Catch the latest news on concerns regarding Gilead's $84,000 hepatitis C treatment drug Sovaldi, the declining sales of traditional cigarettes, and why prior authorization could be hurting the health care system
Catch the latest news on concerns regarding Gilead's $84,000 hepatitis C treatment drug Sovaldi, the declining sales of traditional cigarettes, and why prior authorization could be hurting the health care system
By ACSH Staff